Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

BACKGROUND: In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Sekulic, Aleksandar, Migden, Michael R., Basset-Seguin, Nicole, Garbe, Claus, Gesierich, Anja, Lao, Christopher D., Miller, Chris, Mortier, Laurent, Murrell, Dedee F., Hamid, Omid, Quevedo, Jorge F., Hou, Jeannie, McKenna, Edward, Dimier, Natalie, Williams, Sarah, Schadendorf, Dirk, Hauschild, Axel
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5433030/
https://ncbi.nlm.nih.gov/pubmed/28511673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3286-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados